大葉大學圖書館 |

Algae-based biopharmaceuticals[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.3298
書名/作者:	Algae-based biopharmaceuticals/ by Sergio Rosales-Mendoza.
作者:	Rosales-Mendoza, Sergio.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	x, 166 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Biopharmaceutics.
標題:	Algae - Biotechnology.
標題:	Pharmaceutical biotechnology.
標題:	Life Sciences.
標題:	Plant Breeding/Biotechnology.
標題:	Freshwater & Marine Ecology.
標題:	Pharmaceutical Sciences/Technology.
標題:	Plant Anatomy/Development.
ISBN:	9783319322322
ISBN:	9783319322308
內容註:	The Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field.
摘要、提要註:	This book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1) Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2) In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs.
電子資源:	http://dx.doi.org/10.1007/978-3-319-32232-2

Algae-based biopharmaceuticals[electronic resource] /
Rosales-Mendoza, Sergio.

Algae-based biopharmaceuticals[electronic resource] /by Sergio Rosales-Mendoza. - Cham :Springer International Publishing :2016. - x, 166 p. :ill., digital ;24 cm.

The Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field.

This book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1) Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2) In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs.

ISBN: 9783319322322

Standard No.: 10.1007/978-3-319-32232-2doiSubjects--Topical Terms:

339188
Biopharmaceutics.

LC Class. No.: RM301.4

Dewey Class. No.: 615.3298

Algae-based biopharmaceuticals[electronic resource] /
LDR:03383nam a2200337 a 4500 001 450346
003 DE-He213
005 20161019140328.0
006 m d
007 cr nn 008maaau
008 161210s2016 gw s 0 eng d
020 $a 9783319322322 $q (electronic bk.)
020 $a 9783319322308 $q (paper)
024 7 $a 10.1007/978-3-319-32232-2 $2 doi
035 $a 978-3-319-32232-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.4
072 7 $a PSTL $2 bicssc
072 7 $a TCB $2 bicssc
072 7 $a SCI011000 $2 bisacsh
072 7 $a SCI010000 $2 bisacsh
082 0 4 $a 615.3298 $2 23
090 $a RM301.4 $b .R788 2016
100 1 $a Rosales-Mendoza, Sergio. $3 646399
245 1 0 $a Algae-based biopharmaceuticals $h [electronic resource] / $c by Sergio Rosales-Mendoza.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a x, 166 p. : $b ill., digital ; $c 24 cm.
505 0 $a The Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field.
520 $a This book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1) Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2) In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs.
650 0 $a Biopharmaceutics. $3 339188
650 0 $a Algae $x Biotechnology. $3 511272
650 0 $a Pharmaceutical biotechnology. $3 339187
650 1 4 $a Life Sciences. $3 463509
650 2 4 $a Plant Breeding/Biotechnology. $3 463547
650 2 4 $a Freshwater & Marine Ecology. $3 463526
650 2 4 $a Pharmaceutical Sciences/Technology. $3 464319
650 2 4 $a Plant Anatomy/Development. $3 463546
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-32232-2
950 $a Biomedical and Life Sciences (Springer-11642)